OncoTherapy Science (30O) Price & Analysis

0 Followers

30O Stock Chart & Stats

€0.11

>-€0.01(-4.03%)

At close: Jan 08 4:00 PM EST

€0.11

>-€0.01(-4.03%)

Day’s Range― - ―

52-Week Range€0.06 - €0.18

Previous CloseN/A

Volume0.00

Average Volume (3M)0.00

Market Cap

€52.69M

Enterprise Value€4.85K

Total Cash (Recent Filing)€1.23B

Total Debt (Recent Filing)€37.14M

Price to Earnings (P/E)―

Beta0.89

Next Earnings

Jan 29, 2027

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-3.03

Shares Outstanding408,243,700

10 Day Avg. Volume0

30 Day Avg. Volume0

Financial Highlights & Ratios

PEG Ratio0.68

Price to Book (P/B)3.22

Price to Sales (P/S)8.53

P/FCF Ratio-7.00

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Debt-free Balance SheetZero debt and a 0.0 debt-to-equity ratio reduce fixed financial obligations and preserve flexibility for research investment or partnering activity. This provides a stronger capital cushion than a leveraged structure, although ongoing losses could still erode that advantage over time.

Improved Gross MarginThe return to a slightly positive gross margin suggests some improvement in the economics of reported revenue compared with prior years. If sustained, better gross profitability could help the company retain more cash from future revenue and support progress toward operating breakeven.

Focused Oncology PipelineA focused oncology strategy gives the company a defined scientific direction centered on cancer genomics and targeted therapies. Concentrating resources in a specialized therapeutic area can support coherent pipeline development and create opportunities to commercialize candidates or related technologies through partnerships.

Bears Say

Persistent Cash BurnDeeply negative operating and free cash flow show that the business is consuming cash rather than funding operations internally. Continued burn increases dependence on external funding, potentially limiting strategic flexibility and creating a durable risk to research continuity if financing becomes less available.

Declining And Volatile RevenueVolatile revenue and the latest year-over-year decline indicate that the company does not yet have a consistently expanding revenue base. This makes planning and funding of oncology development more difficult, while reducing visibility into when commercial activity can offset substantial research spending.

Deep Operating LossesOperating losses that are roughly as large as revenue demonstrate that current scale is insufficient to cover the cost structure. Persistent net losses can consume the capital cushion over time, delay self-sustaining operations, and leave future progress dependent on successful development or financing outcomes.

30O FAQ

What was OncoTherapy Science, Inc.’s price range in the past 12 months?

OncoTherapy Science, Inc. lowest stock price was €0.06 and its highest was €0.17 in the past 12 months.

What is OncoTherapy Science, Inc.’s market cap?

OncoTherapy Science, Inc.’s market cap is €52.69M.

When is OncoTherapy Science, Inc.’s upcoming earnings report date?

OncoTherapy Science, Inc.’s upcoming earnings report date is Jan 29, 2027 which is in 137 days.

How were OncoTherapy Science, Inc.’s earnings last quarter?

OncoTherapy Science, Inc. released its earnings results on Aug 07, 2026. The company reported -€0.004 earnings per share for the quarter.

Is OncoTherapy Science, Inc. overvalued?

According to Wall Street analysts OncoTherapy Science, Inc.’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does OncoTherapy Science, Inc. pay dividends?

OncoTherapy Science, Inc. does not currently pay dividends.

What is OncoTherapy Science, Inc.’s EPS estimate?

OncoTherapy Science, Inc.’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does OncoTherapy Science, Inc. have?

OncoTherapy Science, Inc. has 408,243,700 shares outstanding.

What happened to OncoTherapy Science, Inc.’s price movement after its last earnings report?

OncoTherapy Science, Inc. reported an EPS of -€0.004 in its last earnings report. Following the earnings report the stock price went down -7.059%.

Which hedge fund is a major shareholder of OncoTherapy Science, Inc.?

Currently, no hedge funds are holding shares in DE:30O

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

OncoTherapy Science, Inc.

OncoTherapy Science, Inc. engages in research and development of anti-body drugs; and the genome analysis of cancer, liquid biopsy, and development of new immunotherapy in Japan. Its development pipeline includes OTS167, a small molecular compound that targets the maternal embryonic leucine zipper kinase inhibitor that is in Phase I/II clinical trials for the treatment of acute myeloid leukemia, as well as in Phase I clinical trials for the treatment of breast cancer; and OTS964, a small molecule TOPK inhibitor currently under non-clinical stage. The company’s pipeline also comprises cancer peptide vaccines, including S-588410, which completed Phase III clinical trials for the treatment esophageal cancer, as well as Phase II clinical trials for the treatment of bladder cancer; S-488210, which is in Phase I/II clinical trials for the treatment of head and neck cancer; S-588210, which is in Phase I clinical trials for the treatment of solid tumor; and OTSGC-A24, currently in Phase I clinical trials for the treatment of gastric cancer. In addition, it is developing antibody drugs consisting of OTSA101, which is in Phase I clinical trials for synovial sarcoma; and an anti-amyloid beta peptide antibody that completed Phase I clinical trials for Alzheimer’s disease. OncoTherapy Science, Inc. was incorporated in 2001 and is headquartered in Kawasaki, Japan.